- Home
- CET vs IMCR Comparison
CET vs IMCR Comparison
Compare CET & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CET | IMCR |
|---|---|---|
| Founded | 1929 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | CET | IMCR |
|---|---|---|
| Price | $50.40 | $30.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.82 |
| AVG Volume (30 Days) | 36.2K | ★ 355.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.39 |
| Revenue Next Year | N/A | $8.19 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $40.24 | $23.15 |
| 52 Week High | $52.95 | $40.71 |
Technical Indicators
Market Signals| Indicator | CET | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 39.99 |
| Support Level | $49.88 | N/A |
| Resistance Level | $51.02 | $34.86 |
| Average True Range (ATR) | 0.88 | 1.44 |
| MACD | -0.16 | -0.20 |
| Stochastic Oscillator | 11.85 | 24.64 |
Price Performance
Historical ComparisonAbout CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.